Caidya Taps New COO to Drive Global Trials, Deepen APAC Foothold

RALEIGH, NC – February 23, 2026 – Global clinical research organization (CRO) Caidya has appointed industry veteran Michael Clay as its new chief operating officer, a strategic move designed to bolster its global operational delivery and reinforce its significant presence in the critical Asia-Pacific clinical trial landscape.

Clay will take the helm of Caidya’s worldwide operational delivery, client engagement model, and execution strategy. The appointment signals the mid-sized CRO’s ambition to enhance its ability to serve innovative biopharmaceutical companies across the U.S., Europe, and its well-established Asia-Pacific network, particularly in China.

A Strategic Play for Global Operations

In a highly competitive global CRO market projected to reach over $140 billion by 2031, mid-sized players like Caidya are carving out their niche by offering a blend of global reach and specialized, agile service. Clay's appointment is a pivotal part of this strategy, aiming to scale operations without sacrificing the partner-level collaboration that differentiates Caidya from its larger competitors like IQVIA and ICON.

This leadership enhancement follows a period of significant strategic investment. Caidya recently secured a $165 million growth investment from Rubicon Founders, a healthcare-focused investment firm. The capital is earmarked to fuel organic expansion, explore strategic acquisitions, and enhance proprietary clinical technologies. Bringing in a COO with Clay's track record in global execution aligns directly with this mandate to accelerate growth and expand market presence.

Caidya, formed through the 2021 merger of dMed and Clinipace, positions itself as a product development partner for biopharma innovators, specializing in complex therapeutic areas such as oncology, hematology, and rare diseases. The addition of a COO focused on operational rigor is expected to strengthen its capacity to manage complex, multi-regional trials with the transparency and agility its clients require.

The Operational Architect

Michael Clay brings a distinguished career in clinical operations to his new role. Most recently, he served as Senior Vice President of Global Project Delivery at Fortrea, where he was responsible for overseeing more than 500 global clinical trials spanning over 60 countries. His extensive resume includes a 15-year tenure at another major global CRO, where he not only led a portfolio of client programs but also served as General Manager for China and subsequently led the entire Asia-Pacific region for five years while based in Singapore.

His hands-on experience is complemented by a deep understanding of the regulatory environment, holding a Master of Science in Jurisprudence in Pharmaceutical & Medical Device Law. This combination of operational leadership and legal acumen is particularly valuable in the increasingly complex world of global drug development.

“Mike’s leadership strengthens one of our most important differentiators — our ability to combine global reach with regional expertise, particularly across APAC and China,” said Barbara Lopez Kunz, CEO of Caidya, in a statement. “His deep understanding of site engagement, global execution, and sponsor partnership will help us scale while preserving the agility, accountability, and transparency our clients value.”

Unlocking the Asia-Pacific Frontier

The strategic emphasis on Clay’s Asia-Pacific experience is no coincidence. The APAC region has become a powerhouse for clinical development, valued at over $16 billion in 2024 and projected to more than double by 2033. It offers access to 60% of the world’s population, providing a vast and diverse patient pool that can significantly accelerate trial recruitment—a major bottleneck in drug development.

However, the region is not without its challenges. Navigating the diverse and evolving regulatory landscapes, managing logistical complexities, and ensuring data quality across different standards requires seasoned expertise. China, in particular, presents a dual opportunity and challenge with its massive patient population, growing biotech sector, and unique regulatory requirements. Clay’s direct experience managing operations on the ground in China and leading the broader APAC region positions Caidya to better guide its partners through these complexities.

“I’m excited to join Caidya at a time when global clinical development is becoming more interconnected and more complex,” Clay stated. “Caidya is strategically positioned to help sponsors accelerate programs while maintaining quality and patient focus.” His appointment reinforces Caidya's value proposition as a differentiated gateway for Western biotechs seeking to execute trials in APAC with confidence.

Building a Leadership Powerhouse

Clay’s arrival is the latest in a series of high-profile appointments aimed at building a formidable global leadership team at Caidya. The company has been systematically strengthening its executive ranks to drive its next phase of growth. This includes the recent appointment of Brandon Pallott as Chief Commercial Officer to spearhead market expansion and Barbara Lopez Kunz’s own transition to CEO in September 2024, after serving on the company's board.

The organization has also bolstered its European presence with the hiring of Mario Bautista as Head of Business Development for Europe and deepened its therapeutic expertise with additions like oncology and hematology subject matter expert Edward Dow, M.D. This pattern of strategic hiring demonstrates a concerted effort to build a leadership team with comprehensive expertise across operational, commercial, and scientific domains, ensuring the company has the talent to match its global ambitions.